Skip to main content
Top

07-03-2017 | Psoriatic arthritis | Article

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry

Journal: Clinical Rheumatology

Authors: Leslie R. Harrold, Bradley S. Stolshek, Sabrina Rebello, David H. Collier, Alex Mutebi, Sally W. Wade, Wendi Malley, Jeffrey D. Greenberg, Carol J. Etzel

Publisher: Springer London

Abstract

Psoriatic arthritis (PsA) is a chronic condition characterized by a diverse set of symptoms, from swollen joints to nail disease to skin disease. A variety of treatment options are available, including tumor necrosis factor inhibitors (TNFis). Little is known about treatment persistence in patients with PsA who initiate TNFi therapy, with and without prior biologic use. This study assessed persistence in these subgroups of patients with PsA and identified factors associated with persistence. This retrospective study utilized data from the Corrona registry of patients with PsA—with or without prior biologic experience—who initiated TNFi therapy between October 1, 2002, and March 21, 2013. Kaplan-Meier curves estimated median time to nonpersistence (discontinuation or switch to another biologic). Cox proportional hazards models identified factors associated with TNFi nonpersistence. A total of 1241 TNFi initiations were identified: 549 by biologic-naïve and 692 by biologic-experienced patients. Through 4 years of follow-up, more biologic-naïve than biologic-experienced patients remained persistent. Biologic-naïve patients had a greater mean time to nonpersistence compared with biologic-experienced patients: 32 vs 23 months (p = 0.0002). Moderate and high disease activities based on clinical disease activity index and disease duration were associated with persistence in both biologic-naïve and biologic-experienced patients. Additionally, in the biologic-experienced patients, the number of prior medications and skin disease were associated with persistence. The majority of patients with PsA in this study were persistent with their TNFi therapy; biologic-naïve patients had greater persistence compared with biologic-experienced patients. Predictors of persistence differed slightly between biologic-naïve and biologic-experienced patients.
Literature
1.
Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17PubMedPubMedCentral
2.
Lloyd P, Ryan C, Menter A (2012) Psoriatic arthritis: an update. Arthritis 2012:176298CrossRefPubMedPubMedCentral
3.
Wilson FC, Icen M, Crowson CS et al (2009) Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 36:361–367CrossRefPubMedPubMedCentral
4.
Gottlieb A, Korman NJ, Gordon KB et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58:851–864CrossRefPubMed
5.
Ogale S, Hitraya E, Henk HJ (2011) Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 12:204CrossRefPubMedPubMedCentral
6.
Ceponis A, Kavanaugh A (2010) Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg 29:56–62CrossRefPubMed
7.
Gossec L, Smolen JS, Ramiro S et al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499–510CrossRefPubMed
8.
Burudpakdee C, Khan ZM, Gala S et al (2015) Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis. Patient Prefer Adherence 9:435–448CrossRefPubMedPubMedCentral
9.
Contreras-Yanez I, Cabiedes J, Villa AR et al (2010a) Persistence on therapy is a major determinant of patient-, physician- and laboratory-reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol 28:748–751PubMed
10.
Contreras-Yanez I, Pascual-Ramos V (2015) Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther 17:177CrossRefPubMedPubMedCentral
11.
Contreras-Yanez I, Ponce De Leon S, Cabiedes J et al (2010b) Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 340:282–290CrossRefPubMed
12.
Fernandez-Nebro A, Irigoyen MV, Urena I et al (2007) Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 34:2334–2342PubMed
13.
Kievit W, Fransen J, Adang EM et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50:196–203CrossRef
14.
Waimann CA, Marengo MF, de Achaval S et al (2013) Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum 65:1421–1429CrossRefPubMedPubMedCentral
15.
Gelfand JM, Gladman DD, Mease PJ et al (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53:573CrossRefPubMed
16.
Liu JT, Yeh HM, Liu SY et al (2014) Psoriatic arthritis: epidemiology, diagnosis, and treatment. World J Orthop 5:537–543CrossRefPubMedPubMedCentral
17.
Gomez-Reino JJ, Carmona L (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29CrossRefPubMedPubMedCentral
18.
Karlsson JA, Kristensen LE, Kapetanovic MC et al (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47:507–513CrossRef
19.
Navarro-Sarabia F, Ruiz-Montesinos D, Hernandez B et al (2009) DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMC Musculoskelet Disord 10:91CrossRefPubMedPubMedCentral
20.
Rendas-Baum R, Wallenstein GV, Koncz T et al (2011) Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors. Arthritis Res Ther 13:R25CrossRefPubMedPubMedCentral
21.
Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11:276–289CrossRefPubMed
22.
Tanaka Y, Kubo S, Yamanaka H et al (2014) Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia® as biological intensive treatment for RA (ORBIT) study. Mod Rheumatol 24:754–762CrossRefPubMed
23.
Kavanaugh A, Mease PJ, Gomez-Reino JJ et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026CrossRefPubMedPubMedCentral
24.
Glintborg B, Ostergaard M, Krogh NS et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO registry. Arthritis Rheum 65:1213–1223CrossRefPubMed
25.
Mease PJ, Collier DH, Saunders KC et al (2015) Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open 1:e000181CrossRefPubMedPubMedCentral
26.
Zhang J, Shan Y, Reed G et al (2011) Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken) 63:1672–1679CrossRef
27.
Curtis JR, Chen L, Bharat A et al (2014) Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken) 66:1790–1798CrossRef